
# The National Academies of SCIENCES • ENGINEERING • MEDICINE



## Planning Committee Members

Sara Rosenbaum (chair), George Washington University
Linda Brady, National Institutes of Health
Betty Diamond, Hofstra Northwell School of Medicine
Sarah Morris, National Institutes of Health
Ralph Nitkin, National Institutes of Health
Patricia Owens, Health and Disability Policy and Programs
Sarah Ruiz, National Institute on Disability, Independent Living, and Rehabilitation Research
Ira Shoulson, University of Rochester
Robert Wallace, University of lowa

Staff: Tracy Lustig, Cyndi Trang, Joseph Goodman, Sharyl Nass

**Sponsor:** Social Security Administration

### Statement of Task

The workshop will facilitate a discussion focused on the use of biomarkers to establish the presence and severity of disability. The workshop will feature invited presentations and discussions on topics including:

- A general overview of non-genetic biomarkers and the current and potential purposes for their use.
- How health care professionals now use non-genetic biomarkers as diagnostic/prognostic tools and severity indicators in the following physical and mental impairments and summarize the supporting research in fibromyalgia, arthritis, posttraumatic stress disorder, major depression, schizophrenia, and chronic pain.
- The legal and ethical implications associated with non-genetic biomarker use in clinical decision-making.

## Agenda

#### July 21, 2020

- Session 1: Overview of Biomarkers
- Session 2: Bioethical and Legal Considerations with the Use of Biomarkers to Establish Presence and Severity of Impairments
- Session 3: State of the Science on Biomarkers to Establish Presence and Severity of Impairments: Part I
- Session 4: State of the Science on Biomarkers to Establish Presence and Severity of Impairments: Part II
- Session 5: Reactor Panel